Clinical Trials for Other Solid Tumor

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced solid tumors harboring KRAS G12C mutations—particularly pancreatic, breast, uterine, or epithelial ovarian cancers, and non-small cell lung cancer with combined KRAS G12C and KEAP1 mutations—who have progressed after prior therapy, and treats them with the combination of adagrasib (a selective irreversible KRAS G12C inhibitor) and olaparib (a PARP inhibitor).

ClinicalTrials.gov ID: NCT06130254

An Open-label Phase 1 Study of ASP4396 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic solid tumors harboring the KRAS G12D mutation who have received or declined standard therapies, treating them with ASP4396, a first-in-class intravenous inhibitor designed to block abnormal KRAS G12D signaling. Patients must have measurable disease, ECOG 0-1, and meet specific organ function and exclusion criteria.

ClinicalTrials.gov ID: NCT06364696

A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors driven by MAPK pathway alterations (KRAS, HRAS, NRAS, BRAF, CRAF, or NF1), who have exhausted standard therapies and have good performance status, to receive the investigational oral MAPK pathway inhibitor DCC-3084 as monotherapy or in combination with other antitumor agents. Confirmed BRAF mutations are required for participation in certain cohorts.

ClinicalTrials.gov ID: NCT06287463

KB707-02: a Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This study enrolls adults with advanced (stage 3 or 4) NSCLC or other solid tumors affecting the lungs who have progressed after, are intolerant of, or have refused standard therapy, and who have measurable lung lesions and good performance status. Treatment is with inhaled KB707, a gene therapy delivering IL-12 and IL-2 via a non-integrating HSV-1 vector to enhance local anti-tumor immunity, either as monotherapy or in combination with pembrolizumab and/or chemotherapy.

ClinicalTrials.gov ID: NCT06228326

Phase II Trial of Photon Craniospinal Irradiation for Leptomeningeal Disease Secondary to Solid Tumor Malignancy

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with leptomeningeal disease secondary to breast cancer or non-small cell lung cancer who have adequate performance status and organ function, and treats them with photon craniospinal irradiation using VMAT, an advanced conformal radiation therapy technique. All patients receive 10 fractions of CSI over 10 to 20 days to assess efficacy and safety in controlling central nervous system progression.

ClinicalTrials.gov ID: NCT06910761

A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Eligible patients are adults with stage IV, EGFR inhibitor-naive NSCLC harboring sensitizing EGFR mutations (exon 19 deletion or L858R) and good performance status, who receive single-agent osimertinib, an oral third-generation, irreversible EGFR tyrosine kinase inhibitor. The study includes mandatory tumor biopsies before treatment and at progression for genomic analysis.

ClinicalTrials.gov ID: NCT03586453

A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent NSCLC

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with previously untreated metastatic or recurrent non-small cell lung cancer (NSCLC) without targetable mutations, testing two dosing regimens of subcutaneous nivolumab (a PD-1 inhibitor) in combination with intravenous ipilimumab (a CTLA-4 inhibitor) and standard chemotherapy. Patients must have measurable disease and good performance status, and those with untreated CNS metastases or active autoimmune disease are excluded.

ClinicalTrials.gov ID: NCT06946797

Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic NSCLC, melanoma, endometrial cancer, or HNSCC who have progressed after standard therapies including prior anti-PD-1/L1 agents, and evaluates the combination of STC-15 (an oral METTL3 inhibitor targeting RNA methylation) plus toripalimab (anti-PD-1 antibody). Eligible patients must have measurable disease, ECOG 0–1, and no active CNS disease.

ClinicalTrials.gov ID: NCT06975293

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with recurrent or second primary tumors in body sites previously treated with radiotherapy—including CNS, head and neck, breast, thoracic, GI, GU, and gynecological cancers—to evaluate reirradiation using pencil beam scanning proton therapy, which aims to provide effective tumor control with reduced toxicity compared to standard photon techniques. No investigational drugs are included, and some cohorts may not allow concurrent chemotherapy.

ClinicalTrials.gov ID: NCT05313191

A Global, Multicenter, Three Arms, Open-label Randomized Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension Compared to Taxotere® (Docetaxel Injection Concentrate) in Triple-negative Breast Cancer Patients With Locally Advanced or Metastatic Breast Cancer After Failure to Prior Chemotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls patients with locally advanced or metastatic triple-negative breast cancer who have progressed after prior chemotherapy, randomizing them to receive either nanosomal docetaxel lipid suspension (a lipid-based docetaxel formulation designed to reduce toxicity and hypersensitivity) at two different doses or standard docetaxel (Taxotere), with all treatments given every 3 weeks until progression or unacceptable toxicity. Prior docetaxel in the metastatic setting and active CNS metastases (except asymptomatic) are exclusion criteria.

ClinicalTrials.gov ID: NCT03671044